Sunday, November 24, 2024 5:00:06 PM
Yes. Odd indeed, although iirc, they later found 935 failed the meet primary because healthy patients usually recovered themselves after day 2 anyways so adminstering them the drug after 48 hrs wasn’t useful … or something to that effect
if now even PED and high risk, which would have weaker immune, also failed to show clinical benefits, that would put the whole RSV program in doubt as one can easily imply 235 will run into same issue as well - Which would make his answer even more odd and somewhat foolish.
if now even PED and high risk, which would have weaker immune, also failed to show clinical benefits, that would put the whole RSV program in doubt as one can easily imply 235 will run into same issue as well - Which would make his answer even more odd and somewhat foolish.
Recent ENTA News
- Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria • Business Wire • 04/13/2026 11:00:00 AM
- Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 • Business Wire • 04/07/2026 11:00:00 AM
- Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) • Business Wire • 03/30/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:20:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:18:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:14:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:05:29 PM
- Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference • Business Wire • 03/03/2026 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/23/2026 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:31:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:29:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:28:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:27:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/11/2026 09:43:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:00:44 PM
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting • Business Wire • 02/10/2026 12:00:00 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 • Business Wire • 02/09/2026 09:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2026 09:10:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2026 09:05:32 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/20/2026 09:42:25 PM
